Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis

Bibliographic Information
Authors: Balata M.; Sugiura A.; Hassan M.; Rady M.; Christoph M.; Ibrahim K.; Becher M.U.; Youssef A.
Journal: Clinical Research in Cardiology
Publisher: Springer Science and Business Media Deutschland GmbH
Publication Date: 10 June 2025
Volume / Issue: Volume 115 / Issue 9
Pages: 1533–1542
ISSN: 18610684
DOI: 10.1007/s00392-025-02694-5
Scopus: View on Scopus
PubMed: 40493069
Document Type: Article
Authors and Affiliations
Balata M., University Hospital Bonn, Venusberg-Campus 1, Bonn, 53127, Germany, Department of Internal Medicine and Cardiology, University Hospital Rostock, Ernst-Heydemann-Straße 6, Rostock, 18057, Germany; Sugiura A., University Hospital Bonn, Venusberg-Campus 1, Bonn, 53127, Germany; Hassan M., Department of Immunology, Theodor Bilharz Research Institute, Giza, Egypt; Rady M., Department of Internal Medicine and Cardiology, City Chemnitz Teaching Hospital, Medical Campus of the Technical University of Dresden, Bürgerstraße 2, Chemnitz, 09113, Germany; Christoph M., Department of Internal Medicine and Cardiology, City Chemnitz Teaching Hospital, Medical Campus of the Technical University of Dresden, Bürgerstraße 2, Chemnitz, 09113, Germany; Ibrahim K., Department of Internal Medicine and Cardiology, City Chemnitz Teaching Hospital, Medical Campus of the Technical University of Dresden, Bürgerstraße 2, Chemnitz, 09113, Germany; Becher M.U., University Hospital Bonn, Venusberg-Campus 1, Bonn, 53127, Germany, Department of Internal Medicine and Cardiology, City Hospital Solingen, Gotenstraße 1, Solingen, 42653, Germany; Youssef A., Department of Internal Medicine and Cardiology, City Chemnitz Teaching Hospital, Medical Campus of the Technical University of Dresden, Bürgerstraße 2, Chemnitz, 09113, Germany
Abstract
Background and objective: Obesity is common in heart failure (HF), worsening quality of life and depressive symptoms. While semaglutide, a GLP-1 agonist, aids weight loss in obese adults, its impact on health and mood in obese HF patients is unclear. This study evaluated semaglutide’s effects on body weight, health status, and mood in obese HF patients over one year. Methods: A retrospective analysis was conducted on 122 obese HF patients treated consecutively with semaglutide between January 2019 and August 2023. The primary endpoints were changes in body mass index (BMI), Hospital Anxiety and Depression Scale (HADS) scores, and Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS) from baseline to one year. Secondary endpoints included changes in NYHA functional class and NT-proBNP levels. Results: Semaglutide treatment resulted in a significant weight reduction at one year, with a mean BMI decrease of −2.23 kg/m2 (95% CI −2.71 to −1.75; p < 0.001). This weight reduction was consistent across patients with baseline BMI < 35 kg/m2 and ≥ 35 kg/m2 (p for interaction = 0.26). HADS anxiety scores decreased from a baseline of 5 points (IQR: 2–8) to 3 points (IQR: 1–7; p = 0.037), while HADS depression scores decreased from 6 points (IQR: 3–8) to 3 points (IQR: 1–6; p < 0.001). KCCQ-OSS scores improved from 62 points (IQR: 52–77) at baseline to 82 points (IQR: 55–95; p < 0.001) at one year. These improvements in HADS depression and KCCQ-OSS scores were consistent across all subgroups, including those with baseline LVEF (≥ 50% or < 50%), BMI (≥ 35 kg/m2 or < 35 kg/m2), ischemic versus non-ischemic cardiomyopathy, and the presence or absence of diabetes. Additionally, significant improvements in NYHA class and NT-proBNP levels were observed at one year. Conclusion: Semaglutide significantly improves health status and mood in obese heart failure patients, with these improvements strongly correlating with weight loss. © Springer-Verlag GmbH Germany, part of Springer Nature 2025.
Keywords
Depression; Glucagon-like peptide 1 receptor agonist; Health status; Heart failure; Semaglutide; Weight reduction; Affect; Aged; Body Mass Index; Female; Glucagon-Like Peptides; Humans; Male; Middle Aged; Obesity; Quality of Life; Retrospective Studies; Treatment Outcome; Weight Loss; aldosterone antagonist; amino terminal pro brain natriuretic peptide; beta adrenergic receptor blocking agent; cholesterol; diuretic agent; glucagon like peptide 1 receptor agonist; hemoglobin A1c; sodium glucose cotransporter 2 inhibitor; triacylglycerol; glucagon like peptide; adult; anxiety; Article; body mass; body weight; body weight loss; cohort analysis; controlled study; diabetes mellitus; diastolic blood pressure; drug dose escalation; estimated glomerular filtration rate; follow up; health outcome; heart left ventricle ejection fraction; Hospital Anxiety and Depression Scale; Hospital Anxiety and Depression Scale-Anxiety; human; hypertension; ischemic cardiomyopathy; Kansas City Cardiomyopathy Questionnaire; major clinical study; mood; New York Heart Association class; non insulin dependent diabetes mellitus; outcome assessment; physical activity; questionnaire; randomized controlled trial; retrospective study; systolic blood pressure; waist circumference; complication; drug effect; drug therapy; pathophysiology; psychology
Citation Information
Scopus Citations: 2
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
